Exercise in Sjogren, Myositis and Takayasu's Arteritis
|ClinicalTrials.gov Identifier: NCT01501019|
Recruitment Status : Unknown
Verified February 2016 by Bruno Gualano, University of Sao Paulo.
Recruitment status was: Recruiting
First Posted : December 29, 2011
Last Update Posted : February 19, 2016
Exercise may improve physical capacity and health parameters in Primary Syndrome´s Sjogren, Myositis and Takayasu's Arteritis.
Therefore, this study aims to investigate the role of an exercise training program in patients with Primary Syndrome´s Sjogren, Myositis and Takayasu's Arteritis.
|Condition or disease||Intervention/treatment||Phase|
|Primary Sjogren´s Syndrome Myositis||Other: Exercise training||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||60 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Effects of Exercise Training in Primary Sjogren´s Syndrome, Myositis and Takayasu's Arteritis|
|Study Start Date :||October 2011|
|Estimated Primary Completion Date :||July 2016|
|No Intervention: Sjogren and Myositis Control (no control for takayasu's)|
|Experimental: Sjogren, Myositis and Takayasu's Trained||
Other: Exercise training
"Sjöegren arm": 30-60 minutes of combined aerobic and strength exercises, twice a week, moderate intensity.
"Myositis arm": 30 minutes of resistance training combined partial blood flow restriction, twice a week, low intensity.
"Takayasu's arteritis arm": 30-50 minutes of aerobic, twice a week, moderate intensity.
- Aerobic Capacity [ Time Frame: Twelve weeks ]Maximum Oxygen Consumption (VO2Max)
- Muscle strength [ Time Frame: Twelve weeks ]
- Quality of life [ Time Frame: Twelve weeks ]
- Serum anti-inflammatory cytokines [ Time Frame: Twelve weeks ]Interleukin-10
- Serum pro-inflammatory cytokines [ Time Frame: Twelve weeks ]Interleukin-1 (IL-1), interleukin-6 (IL-6), tumor necrosis factor-a (TNF-a)
- Serum inflammatory markers [ Time Frame: Twelve weeks ]erythrocyte sedimentation rate (ESR), c-reactive protein (CRP), aldolase
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01501019
|University of Sao Paulo School of Medicine Clinical Hospital||Recruiting|
|Sao Paulo, Brazil, 05403-010|
|Contact: Thalita Blasques Dassouki, MSc 55 11 2661-8022 firstname.lastname@example.org|
|Principal Investigator: Ana Lucia Sa Pinto, PhD|
|Sub-Investigator: Bruno Gualano, PhD|
|Sub-Investigator: Fernanda R Lima, PhD|
|Sub-Investigator: Hamilton Roschel, PhD|
|Sub-Investigator: Sandra G Pasoto, PhD|